SHANGHAI – Anesiva entered into a joint venture Oct. 14 with Jiangsu Wanbang Biological Pharmaceutical Corp., a subsidiary of Shanghai Fosun Pharmaceuticals, to establish additional manufacturing capacity for the worldwide supply of its fast-acting topical local analgesia Zingo (lidocaine hydrochloride monohydrate).
Continue reading "Anesiva Forms Joint Venture With Wanbang Biological" »
Eli Lilly is gaining a portfolio of molecules targeting the vanilloid-1 receptor, including Phase II candidate GRC 6211, through an agreement with Mumbai, India-based Glenmark Pharmaceuticals, announced Oct. 30.
Continue reading "Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark" »
SHANGHAI – Xian Janssen has launched the TNF inhibitor Remicade (infliximab) in China for use in the treatment of rheumatoid arthritis, ankyloing spondylitis and Crohn’s disease, the company announced Oct. 16.
Continue reading "Xian Janssen launches Remicade In China" »
A cholesterol drug Takeda had planned to file in the first quarter of 2008 has been delayed after elevated transaminase levels were seen in some patients taking a higher dose of the product in clinical trials, the Japanese firm announced Oct. 29. FDA has requested additional clinical trial data on TAK-475 (lapaquistat), a squalene synthase inhibitor.
Continue reading "Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data" »
Kirin Holdings and Kyowa Hakko will seek to bring together each company's strength in biotech to create a global research and development-centered Japanese drug company. The two Tokyo-based companies announced a merger agreement Oct. 22, reflecting the ongoing consolidation of the Japanese drug industry.
Continue reading "Japan's Kirin, Kyowa Merge To Strengthen Biotechnology Focus" »
Tarceva (erlotinib) will launch in Japan in early 2008 after being approved by the Japanese Ministry of Health for the treatment of patients with nonresectable, recurrent and advanced non-small cell lung cancer aggravated following chemotherapy, Roche/OSI announced Oct. 22.
Continue reading "Tarceva Cleared By Japanese Regulators For NSCLC" »
By: Shamnad Basheer
Indian patent law recently landed itself in the eye of a “TRIPS” storm on account of the rejection of a patent application covering Novartis’s famed anticancer drug, Glivec (imatinib mesylate). The rejection stemmed, inter-alia from a unique section in the Indian patent regime (section 3(d)) that prohibits the patenting of new forms of existing pharmaceutical substances that do not demonstrate significantly enhanced “efficacy.”
Continue reading "Insider Analysis: The Glivec Patent Saga – Effectuating “Efficacious” Patent Norms In India" »
SHANGHAI – Pfizer won a trademark dispute against Beijing Herod Bio-tech Co. Sept. 24, with the First Intermediate Court of Beijing ordering Beijing Herod to pay Pfizer 200,000 yuan ($26,666) for infringing Pfizer’s Chinese trademarks.
Continue reading "Pfizer Wins Trademark Lawsuit In China" »
